Adalimumab discontinuation in patients with rheumatoid arthritis after achieving sustained remission
Демидова Н. В., Галушко Е. А., Глухова С. И., Савушкина Н. М., Сатyбалдьев А. М., Черкасова М. В., Хорошко Н. В., Маглеванyи С. В., Гордеев А. В.
Научно-практическая ревматология
Т. 56, Вып. 3, С. 316-320
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.14412/1995-4484-2018-316-320
Аннотация:
Objective: to assess whether adalimumab (AD) can be gradually discontinued during continuous methotrexate (MTX) use in patients with early rheumatoid arthritis (ERA). Subjects and methods. Within the REMARCA (the Russian study of methotrexate and biological agents in early active arthritis) study, the investigators examined 20 patients (17 women and 3 men; median age, 51 [41.5; 56] years) with ERA (disease duration, 10 [5.5; 20] months; DAS28, 5.17 [4.37; 6.51]; 85[%] of the patients were seropositive for rheumatoid factor and 85[%] for anti-cyclic citrullinated peptide antibodies. Results and discussion. All the patients received subcutaneous MTX 25 mg/week. Twelve weeks after beginning therapy with MTX, due to its inefficiency, ADA was added according to the standard scheme. At week 24, the median DAS28 was 3.0 [1.65; 3.73]; 85[%] of the patients achieved remission or low disease activity. After 3 months of ADA therapy, high or moderate disease activity remained in 3 (15[%]) patients; median
Ключевые слова:
Adalimumab; Early rheumatoid arthritis; Remission
Язык текста: Русский
ISSN: 1995-4492
Демидова Н. В.
Галушко Е. А.
Глухова С. И.
Савушкина Н. М.
Сатyбалдьев А. М.
Черкасова М. В.
Хорошко Н. В. Наина Владимировна 1963-
Маглеванyи С. В.
Гордеев А. В.
Demidova N. V.
Galushko E. A.
Glukhova S. I.
Savushkina N. M.
Satybaldyev A. M.
Cherkasova M. V.
Khoroshko N. V. Naina Vladimirovna 1963-
Maglevanyi S. V.
Gordeev A. V.
Adalimumab discontinuation in patients with rheumatoid arthritis after achieving sustained remission
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 56, Вып. 3 С. 316-320
2018
Статья
Adalimumab Early rheumatoid arthritis Remission
Objective: to assess whether adalimumab (AD) can be gradually discontinued during continuous methotrexate (MTX) use in patients with early rheumatoid arthritis (ERA). Subjects and methods. Within the REMARCA (the Russian study of methotrexate and biological agents in early active arthritis) study, the investigators examined 20 patients (17 women and 3 men; median age, 51 [41.5; 56] years) with ERA (disease duration, 10 [5.5; 20] months; DAS28, 5.17 [4.37; 6.51]; 85[%] of the patients were seropositive for rheumatoid factor and 85[%] for anti-cyclic citrullinated peptide antibodies. Results and discussion. All the patients received subcutaneous MTX 25 mg/week. Twelve weeks after beginning therapy with MTX, due to its inefficiency, ADA was added according to the standard scheme. At week 24, the median DAS28 was 3.0 [1.65; 3.73]; 85[%] of the patients achieved remission or low disease activity. After 3 months of ADA therapy, high or moderate disease activity remained in 3 (15[%]) patients; median